Hong Kong-based Guangdong Hengrui Pharmaceuticals’s parent company Jiangsu Hengrui Pharmaceuticals announced that Guangdong Hengrui has received approval from the Chinese National Medical Products Administration (NMPA) for a clinical trial of its HRS-9821 DPI, which the company is developing for the treatment of COPD. The company says that it expects to initiate the trial “in the near future.”
According to the announcement, “HRS-9821 is a small molecule PDE3/PDE4 inhibitor that can effectively inhibit respiratory inflammation and dilate bronchi” and according to Hengrui’s web site, the dry powder formulation is in Phase 1 development. The company notes that ensifentrine inhalation suspension is the only similar product currently approved anywhere in the world for the treatment of COPD.
Read the Jiangsu Hengrui Pharmaceuticals regulatory announcement
